Request Demo
Last update 30 Oct 2025
Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering)
Last update 30 Oct 2025
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms JY43, JY43-2 |
Target |
Action inhibitors |
Mechanism CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Antibody-dependent cellular phagocytosis (ADCP) effects |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 9075449L
The sequence is quoted from: *****
Sequence Code 9946743H
The sequence is quoted from: *****
Related
1
Clinical Trials associated with Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering)CTR20254167
一项随机、双盲、平行对照比较JY43与兆珂®在健康男性受试者中的药代动力学、安全性、耐受性和免疫原性的研究
[Translation] A randomized, double-blind, parallel-controlled study comparing the pharmacokinetics, safety, tolerability, and immunogenicity of JY43 and Zyclopramide in healthy male subjects.
100 Clinical Results associated with Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering)
Login to view more data
100 Translational Medicine associated with Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering)
Login to view more data
100 Patents (Medical) associated with Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering)
Login to view more data
100 Deals associated with Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Multiple Myeloma | Phase 1 | China | 30 Oct 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free